Welcome to our dedicated page for Acutus Medical news (Ticker: AFIB), a resource for investors and traders seeking the latest updates and insights on Acutus Medical stock.
Acutus Medical, Inc. (OTC: AFIB) drives innovation in cardiac electrophysiology through its specialized left-heart access devices and strategic partnerships. This page serves as the definitive source for verified news and press releases directly from the company.
Investors and healthcare professionals will find timely updates on manufacturing agreements, product developments, and operational milestones. Our curated collection ensures access to essential information about AFIB's evidence-based solutions for complex arrhythmias, including its collaboration with Medtronic.
Key updates cover regulatory progress, clinical advancements, and financial developments while maintaining compliance with disclosure standards. All content undergoes rigorous verification to provide reliable insights into the company's focused electrophysiology strategy.
Bookmark this page to stay informed about Acutus Medical's latest achievements in medical device innovation and operational efficiency improvements. Check regularly for authoritative updates from the source.
Acutus Medical (Nasdaq: AFIB) is participating in the 2021 Heart Rhythm Society (HRS) conference from July 28-31 in Boston, offering clinical and educational opportunities. Highlights include a presentation on Pulsed Field Ablation (PFA) technology and a hands-on masterclass for physicians. The company emphasizes its advancements in the treatment of atrial fibrillation using unique mapping and ablation techniques. CEO Vince Burgess noted the importance of HRS for showcasing innovative electrophysiology solutions.
AliveCor and Acutus Medical have announced a partnership aimed at improving the treatment and management of cardiac arrhythmias. The collaboration will explore the integration of data collection tools across cardiology care. A pilot study is set to launch in Q3 2021, focusing on utilizing AliveCor's KardiaMobile device for remote monitoring in complex arrhythmias. The KardiaMobile 6L offers comprehensive ECG capabilities and has been FDA cleared for additional functionalities. This partnership aims to enhance clinical decision-making and improve patient outcomes.
Acutus Medical, Inc. (Nasdaq: AFIB) announced the full exercise of the underwriter's option to purchase an additional 825,000 shares at $14.00 per share, increasing total shares sold in the public offering to 6,325,000. The total gross proceeds reached approximately $88.6 million before expenses. The offering closed on July 26, 2021, following the initial closing on July 19, 2021. Goldman Sachs & Co. LLC managed the offering. Acutus focuses on advancing electrophysiology solutions for cardiac arrhythmias.
Acutus Medical, Inc. (Nasdaq: AFIB) announced the pricing of its underwritten public offering of 5,500,000 shares at $14.00 per share, aiming for gross proceeds of $77.0 million. The offering is set to close on July 19, 2021, subject to customary conditions. Goldman Sachs & Co. LLC is the sole book-running manager for this offering. Additionally, Acutus granted underwriters a 30-day option to buy an extra 825,000 shares. The registration statement was effective as of July 14, 2021. The funds will support Acutus' commitment to advancing arrhythmia management.
Acutus Medical, Inc. (Nasdaq: AFIB) has announced a public offering of 5,500,000 shares of common stock, all being offered by the company. Additionally, underwriters may purchase an extra 825,000 shares. Goldman Sachs & Co. LLC is serving as the sole book-running manager for the transaction. The offering's details will be delineated in a prospectus filed with the SEC. Potential risks affecting the offering include market conditions, regulatory approvals, and economic factors. The company is focused on advancing arrhythmia management through its innovative product offerings.
Acutus Medical reported preliminary results for Q2 2021, estimating net sales between $4.6 million and $4.7 million, a growth of over 300% year-over-year and 30% quarter-over-quarter. The installed base of AcQMap consoles increased to 68, with 70 total consoles by June 30. The company received Investigational Device Exemption to study the AcQBlate catheter. Despite robust sales, the loss from operations is projected at $27 million to $29 million, higher than the previous year's $19.5 million. Cash reserves stand at approximately $81 million.
Acutus Medical (Nasdaq: AFIB) has announced FDA approval to initiate its Atrial Fibrillation Investigational Device Exemption (IDE) clinical trial for the AcQBlate Force Sensing Ablation Catheter and System. This trial aims to enroll 350 subjects and evaluate safety and efficacy for treating both paroxysmal and persistent atrial fibrillation, a condition affecting many patients. With AF ablation procedures projected to increase to 375,000 annually by 2025, Acutus aims to expand its market presence and address a significant need in arrhythmia management.
Acutus Medical, a leader in arrhythmia management, will participate in the 41st Annual William Blair Growth Stock Conference on June 3, 2021, at 12:20 p.m. Eastern Time. The event will be accessible through a live webcast on their investor relations website, with a replay available for 30 days post-presentation. Acutus Medical specializes in innovative solutions for the diagnosis and treatment of cardiac arrhythmias, enhancing the efficiency and effectiveness of electrophysiology practices.
Acutus Medical (Nasdaq: AFIB) announced CE Mark Approval for a suite of electrophysiology products aimed at improving cardiac arrhythmia treatment. The newly approved products include the AcQCross™ family of transseptal crossing devices, AcQGuide® MAX and VUE delivery sheaths, and the next-generation AcQMap® mapping catheter. These innovations enhance procedural efficiency and support the growing demand for cardiac ablations, projected to rise from 350,000 annually to 475,000 by 2025 in Europe. These advances underscore Acutus' commitment to improving arrhythmia management.
Acutus Medical (AFIB) reported first-quarter 2021 revenue of $3.6 million, a significant increase from $1.6 million in Q1 2020. Key developments include a rise in the installed base of AcQMap consoles to 62 and the initiation of the US IDE trial for the AcQBlate system. However, the company faced a net loss of $29.2 million with a gross margin of -94% due to inventory write-offs. For 2021, revenue guidance remains between $22 million and $30 million, with Q2 expectations of $3.8 million to $5 million.
